{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T10:53:46Z","timestamp":1789988026801,"version":"4.0.1"},"reference-count":188,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T00:00:00Z","timestamp":1729468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00210-024-03500-1","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T15:03:18Z","timestamp":1729522998000},"page":"2319-2342","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Glycogen synthase kinase 3 (GSK3) inhibition: a potential therapeutic strategy for Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"398","author":[{"given":"Dipanjan","family":"Karati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyasi","family":"Meur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souvik","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6511-3116","authenticated-orcid":false,"given":"Swarupananda","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biplab","family":"Debnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajal Kumar","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biresh Kumar","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saheli","family":"Naskar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,21]]},"reference":[{"issue":"49","key":"3500_CR1","doi-asserted-by":"publisher","first-page":"12735","DOI":"10.1523\/JNEUROSCI.0575-06.2006","volume":"26","author":"MA Abad","year":"2006","unstructured":"Abad MA, Enguita M, DeGregorio-Rocasolano N, Ferrer I, Trullas R (2006) Neuronal pentraxin 1 contributes to the neuronal damage evoked by amyloid-\u03b2 and is overexpressed in dystrophic neurites in Alzheimer\u2019s brain. J Neurosci 26(49):12735\u201347","journal-title":"J Neurosci"},{"issue":"2","key":"3500_CR2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/brain\/awn312","volume":"132","author":"R Adalbert","year":"2009","unstructured":"Adalbert R, Nogradi A, Babetto E, Janeckova L, Walker SA, Kerschensteiner M, Misgeld T, Coleman MP (2009) Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. Brain 132(2):402\u201316","journal-title":"Brain"},{"issue":"16","key":"3500_CR3","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1523\/JNEUROSCI.6154-09.2010","volume":"30","author":"YZ Alabed","year":"2010","unstructured":"Alabed YZ, Pool M, Tone SO, Sutherland C, Fournier AE (2010) GSK3\u03b2 regulates myelin-dependent axon outgrowth inhibition through CRMP4. J Neurosci 30(16):5635\u201343","journal-title":"J Neurosci"},{"issue":"4","key":"3500_CR4","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3390\/ph15040426","volume":"15","author":"TF Ali","year":"2022","unstructured":"Ali TF, Ciftci HI, Radwan MO, Roshdy E, Shawky AM, Abourehab MA, Tateishi H, Otsuka M, Fujita M (2022) Discovery of azaindolin-2-one as a dual inhibitor of GSK3\u03b2 and tau aggregation with potential neuroprotective activity. Pharmaceuticals 15(4):426","journal-title":"Pharmaceuticals"},{"issue":"3","key":"3500_CR5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1002\/jnr.10737","volume":"74","author":"TM Allinson","year":"2003","unstructured":"Allinson TM, Parkin ET, Turner AJ, Hooper NM (2003) ADAMs family members as amyloid precursor protein \u03b1-secretases. J Neurosci Res 74(3):342\u201352","journal-title":"J Neurosci Res"},{"issue":"2","key":"3500_CR6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.nbd.2010.04.011","volume":"39","author":"CD Aluise","year":"2010","unstructured":"Aluise CD, Robinson RA, Beckett TL, Murphy MP, Cai J, Pierce WM, Markesbery WR, Butterfield DA (2010) Preclinical Alzheimer disease: brain oxidative stress, A\u03b2 peptide and proteomics. Neurobiol Dis 39(2):221\u20138","journal-title":"Neurobiol Dis"},{"issue":"1","key":"3500_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.yexcr.2004.02.028","volume":"297","author":"AR Alvarez","year":"2004","unstructured":"Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M, Inestrosa NC (2004) Wnt-3a overcomes \u03b2-amyloid toxicity in rat hippocampal neurons. Exp Cell Res 297(1):186\u201396","journal-title":"Exp Cell Res"},{"issue":"3","key":"3500_CR8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/0197-4580(94)00160-3","volume":"16","author":"BH Anderton","year":"1995","unstructured":"Anderton BH, Brion JP, Couck AM, Davis DR, Gallo JM, Hanger DP, Ladhani K, Latimer DA, Lewis C, Lovestone S, Marquardt B (1995May 1) Modulation of PHF-like tau phosphorylation in cultured neurones and transfected cells. Neurobiol Aging 16(3):389\u201397","journal-title":"Neurobiol Aging"},{"key":"3500_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1042\/bss0670073","volume":"67","author":"BH Anderton","year":"2001","unstructured":"Anderton BH, Betts J, Blackstock WP, Brion JP, Chapman S, Connell J, Dayanandan R, Gallo JM, Gibb G, Hanger DP, Hutton M (2001) Sites of phosphorylation in tau and factors affecting their regulation. InBiochemical Soc Symp 67:73\u201380 Portland Press Limited","journal-title":"InBiochemical Soc Symp"},{"key":"3500_CR10","doi-asserted-by":"crossref","unstructured":"Atri A (2019) Current and future treatments in Alzheimer\u2019s disease. InSemin Neurol 39(02): 227-240. Thieme Medical Publishers","DOI":"10.1055\/s-0039-1678581"},{"issue":"11","key":"3500_CR11","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1586\/14737175.7.11.1527","volume":"7","author":"J Avila","year":"2007","unstructured":"Avila J, Hern\u00e1ndez F (2007) GSK-3 inhibitors for Alzheimer\u2019s disease. Exp Rev Neurother 7(11):1527\u201333","journal-title":"Exp Rev Neurother"},{"issue":"13","key":"3500_CR12","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1038\/sj.emboj.7600251","volume":"23","author":"L Baki","year":"2004","unstructured":"Baki L, Shioi J, Wen P, Shao Z, Schwarzman A, Gama-Sosa M, Neve R, Robakis NK (2004) PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J 23(13):2586\u201396","journal-title":"The EMBO journal."},{"issue":"2","key":"3500_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1523\/JNEUROSCI.4067-07.2008","volume":"28","author":"L Baki","year":"2008","unstructured":"Baki L, Neve RL, Shao Z, Shioi J, Georgakopoulos A, Robakis NK (2008) Wild-type but not FAD mutant presenilin-1 prevents neuronal degeneration by promoting phosphatidylinositol 3-kinase neuroprotective signaling. J Neurosci 28(2):483\u201390","journal-title":"J Neurosci"},{"issue":"3","key":"3500_CR14","first-page":"276","volume":"8","author":"ME Bamberger","year":"2002","unstructured":"Bamberger ME, Landreth GE (2002) Inflammation, apoptosis, and Alzheimer\u2019s disease. Neuroscientist 8(3):276\u201383","journal-title":"Neuroscientist"},{"issue":"1","key":"3500_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.neurobiolaging.2003.03.001","volume":"25","author":"G Bartzokis","year":"2004","unstructured":"Bartzokis G (2004) Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer\u2019s disease. Neurobiol Aging 25(1):5\u201318","journal-title":"Neurobiol Aging."},{"issue":"3","key":"3500_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/archneur.60.3.393","volume":"60","author":"G Bartzokis","year":"2003","unstructured":"Bartzokis G, Cummings JL, Sultzer D, Henderson VW, Nuechterlein KH, Mintz J (2003) White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. Arch Neurol 60(3):393\u20138","journal-title":"Arch Neurol"},{"issue":"51","key":"3500_CR17","doi-asserted-by":"publisher","first-page":"6817","DOI":"10.1038\/sj.onc.1209942","volume":"25","author":"DS Basseres","year":"2006","unstructured":"Basseres DS, Baldwin AS (2006) Nuclear factor-\u03baB and inhibitor of \u03baB kinase pathways in oncogenic initiation and progression. Oncogene 25(51):6817\u201330","journal-title":"Oncogene"},{"key":"3500_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11481-005-9006-y","volume":"1","author":"MJ Bellizzi","year":"2006","unstructured":"Bellizzi MJ, Lu SM, Gelbard HA (2006) Protecting the synapse: evidence for a rational strategy to treat HIV-1 associated neurologic disease. J Neuroimm Pharmacol 1:20\u201331","journal-title":"J Neuroimm Pharmacol"},{"issue":"3","key":"3500_CR19","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.neuroscience.2010.05.044","volume":"169","author":"E Beurel","year":"2010","unstructured":"Beurel E, Jope RS (2010) Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes. Neuroscience 169(3):1063\u201370","journal-title":"Neurosci"},{"issue":"6","key":"3500_CR20","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1111\/j.1471-4159.2004.02422.x","volume":"89","author":"RV Bhat","year":"2004","unstructured":"Bhat RV, Budd Haeberlein SL, Avila J (2004) Glycogen synthase kinase 3: a drug target for CNS therapies. J Neurochem 89(6):1313\u20137","journal-title":"J Neurochem"},{"issue":"s1","key":"3500_CR21","doi-asserted-by":"publisher","first-page":"S547","DOI":"10.3233\/JAD-179934","volume":"64","author":"RV Bhat","year":"2018","unstructured":"Bhat RV, Andersson U, Andersson S, Knerr L, Bauer U, Sundgren-Andersson AK (2018) The conundrum of GSK3 inhibitors: is it the dawn of a new beginning? J Alzheimer\u2019s Dis 64(s1):S547-54","journal-title":"J Alzheimer's Dis"},{"issue":"60","key":"3500_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ejmech.2012.12.014","volume":"1","author":"A Bidon-Chanal","year":"2013","unstructured":"Bidon-Chanal A, Fuertes A, Alonso D, P\u00e9rez DI, Mart\u00ednez A, Luque FJ, Medina M (2013) Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin. Eur J Med Chem 1(60):479\u201389","journal-title":"Eur J Med Chem"},{"issue":"1","key":"3500_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0014-5793(95)00580-3","volume":"369","author":"D Bossemeyer","year":"1995","unstructured":"Bossemeyer D (1995) Protein kinases\u2014structure and function. FEBS Lett 369(1):57\u201361","journal-title":"FEBS Letters."},{"key":"3500_CR24","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1042\/bss0670081","volume":"67","author":"JP Brion","year":"2001","unstructured":"Brion JP, Anderton BH, Authelet M, Dayanandan R, Leroy K, Lovestone S, Octave JN, Pradier L, Touchet N, Tremp G (2001) Neurofibrillary tangles and tau phosphorylation. InBiochemical Soc Symp 67:81\u201388 Portland Press Limited","journal-title":"InBiochemical Soc Symp"},{"issue":"10","key":"3500_CR25","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","volume":"23","author":"MA Busche","year":"2020","unstructured":"Busche MA, Hyman BT (2020) Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease. Nat Neurosci 23(10):1183\u201393","journal-title":"Nat Neurosci"},{"issue":"48","key":"3500_CR26","doi-asserted-by":"publisher","first-page":"49571","DOI":"10.1074\/jbc.C400442200","volume":"279","author":"H Buss","year":"2004","unstructured":"Buss H, Dorrie A, Schmitz ML, Frank R, Livingstone M, Resch K, Kracht M (2004) Phosphorylation of serine 468 by GSK-3\u03b2 negatively regulates basal p65 NF-\u03baB activity. J Biol Chem 279(48):49571\u20134","journal-title":"J Biol Chem"},{"issue":"7","key":"3500_CR27","doi-asserted-by":"publisher","first-page":"864","DOI":"10.2174\/156720512802455386","volume":"9","author":"Z Cai","year":"2012","unstructured":"Cai Z, Zhao Y, Zhao B (2012) Roles of glycogen synthase kinase 3 in Alzheimer\u2019s disease. Curr Alzheimer Res 9(7):864\u201379","journal-title":"Curr Alzheimer Res"},{"issue":"4","key":"3500_CR28","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1038\/nprot.2006.327","volume":"1","author":"AE Cardona","year":"2006","unstructured":"Cardona AE, Huang D, Sasse ME, Ransohoff RM (2006) Isolation of murine microglial cells for RNA analysis or flow cytometry. Nat Protoc 1(4):1947\u201351","journal-title":"Nat Protoc"},{"issue":"5","key":"3500_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0165-6147(03)00100-7","volume":"24","author":"A Caricasole","year":"2003","unstructured":"Caricasole A, Copani A, Caruso A, Caraci F, Iacovelli L, Sortino MA, Terstappen GC, Nicoletti F (2003) The Wnt pathway, cell-cycle activation and \u03b2-amyloid: novel therapeutic strategies in Alzheimer\u2019s disease? Trends Pharmacol Sci 24(5):233\u20138","journal-title":"Trends Pharmacol Sci"},{"issue":"26","key":"3500_CR30","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1523\/JNEUROSCI.1381-04.2004","volume":"24","author":"A Caricasole","year":"2004","unstructured":"Caricasole A, Copani A, Caraci F, Aronica E, Rozemuller AJ, Caruso A, Storto M, Gaviraghi G, Terstappen GC, Nicoletti F (2004) Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer\u2019s brain. J Neurosci 24(26):6021\u20137","journal-title":"J Neurosci"},{"issue":"11","key":"3500_CR31","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/nrd2999","volume":"8","author":"LK Chico","year":"2009","unstructured":"Chico LK, Van Eldik LJ, Watterson DM (2009) Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discover 8(11):892\u2013909","journal-title":"Nat Rev Drug Discover"},{"issue":"2","key":"3500_CR32","first-page":"495","volume":"19","author":"Z Chong","year":"2004","unstructured":"Chong Z, Maiese KW (2004) Targeting WNT, protein kinase B, and mitochondrial membrane integrity to foster cellular survival in the nervous system. Histol Histopathol 19(2):495","journal-title":"Histol Histopathol"},{"issue":"48","key":"3500_CR33","doi-asserted-by":"publisher","first-page":"50176","DOI":"10.1074\/jbc.C400412200","volume":"279","author":"AR Cole","year":"2004","unstructured":"Cole AR, Knebel A, Morrice NA, Robertson LA, Irving AJ, Connolly CN, Sutherland C (2004) GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. J Biol Chem 279(48):50176\u201380","journal-title":"J Biol Chem"},{"issue":"3","key":"3500_CR34","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.nlm.2007.04.006","volume":"88","author":"L Conboy","year":"2007","unstructured":"Conboy L, Seymour CM, Monopoli MP, O\u2019Sullivan NC, Murphy KJ, Regan CM (2007) Notch signalling becomes transiently attenuated during long-term memory consolidation in adult Wistar rats. Neurobiol Learn Mem 88(3):342\u201351","journal-title":"Neurobiol Learn Mem"},{"issue":"1","key":"3500_CR35","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3233\/ADR-190135","volume":"3","author":"TK Das","year":"2019","unstructured":"Das TK, Jana P, Chakrabarti SK, Abdul Hamid MR (2019) Curcumin downregulates GSK3 and Cdk5 in scopolamine-induced Alzheimer\u2019s disease rats abrogating A\u03b2 40\/42 and tau hyperphosphorylation. J Alzheimer\u2019s Dis Rep 3(1):257\u201367","journal-title":"J Alzheimer's Dis Rep"},{"issue":"15","key":"3500_CR36","doi-asserted-by":"publisher","first-page":"11590","DOI":"10.1074\/jbc.M607483200","volume":"282","author":"FG De Felice","year":"2007","unstructured":"De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL (2007) A\u03b2 oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282(15):11590\u2013601","journal-title":"J Biol Chem"},{"issue":"1","key":"3500_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0165-0173(00)00021-7","volume":"33","author":"GV De Ferrari","year":"2000","unstructured":"De Ferrari GV, Inestrosa NC (2000) Wnt signaling function in Alzheimer\u2019s disease. Brain Res Rev 33(1):1\u20132","journal-title":"Brain Res Rev"},{"issue":"3","key":"3500_CR38","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.neurobiolaging.2005.03.003","volume":"27","author":"P De Sarno","year":"2006","unstructured":"De Sarno P, Bijur GN, Zmijewska AA, Li X, Jope RS (2006) In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors. Neurobiol Aging 27(3):413\u201322","journal-title":"Neurobiol Aging"},{"issue":"4","key":"3500_CR39","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1021\/acsmedchemlett.8b00507","volume":"10","author":"A De Simone","year":"2019","unstructured":"De Simone A, La Pietra V, Betari N, Petragnani N, Conte M, Daniele S, Pietrobono D, Martini C, Petralla S, Casadei R, Davani L (2019) Discovery of the first-in-class GSK-3\u03b2\/HDAC dual inhibitor as disease-modifying agent to combat Alzheimer\u2019s disease. ACS Med Chem Lett 10(4):469\u201374","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"3500_CR40","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1021\/acs.jmedchem.0c00931","volume":"64","author":"A De Simone","year":"2020","unstructured":"De Simone A, Tumiatti V, Andrisano V, Milelli A (2020) Glycogen synthase kinase 3\u03b2: a new gold rush in anti-Alzheimer\u2019s disease Multitarget Drug Discovery? Miniperspective. J Med Chem 64(1):26\u20134","journal-title":"J Med Chem"},{"key":"3500_CR41","doi-asserted-by":"crossref","unstructured":"Deshpande R (2022) Recent advances in approved, withdrawn, experimental and. investigational drugs in clinical trials for Alzheimer\u2019s disease. Med Anal Chem Int J 6(1):000174","DOI":"10.23880\/macij-16000174"},{"issue":"2","key":"3500_CR42","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1074\/jbc.M111.306472","volume":"287","author":"JM Dom\u00ednguez","year":"2012","unstructured":"Dom\u00ednguez JM, Fuertes A, Orozco L, del Monte-Mill\u00e1n M, Delgado E, Medina M (2012) Evidence for irreversible inhibition of glycogen synthase kinase-3\u03b2 by tideglusib. J Biol Chem 287(2):893\u2013904","journal-title":"J Biol Chem"},{"issue":"134","key":"3500_CR43","doi-asserted-by":"publisher","first-page":"106446","DOI":"10.1016\/j.bioorg.2023.106446","volume":"1","author":"Y Dong","year":"2023","unstructured":"Dong Y, Lu J, Zhang S, Chen L, Wen J, Wang F, Mao Y, Li L, Zhang J, Liao S, Dong L (2023) Design, synthesis and bioevaluation of 1, 2, 4-thiadiazolidine-3, 5-dione derivatives as potential GSK-3\u03b2 inhibitors for the treatment of Alzheimer\u2019s disease. Bioorgan Chem 1(134):106446","journal-title":"Bioorgan Chem"},{"key":"3500_CR44","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1096\/fasebj.30.1_supplement.814.5","volume":"30","author":"J Donley","year":"2016","unstructured":"Donley J, Hurt W, Stockert A (2016) Effects of cinnamon extract on glycogen synthase kinase 3 phosphorylation of tau. FASEB J 30:814\u20135","journal-title":"The FASEB J"},{"issue":"3","key":"3500_CR45","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S1471-4914(01)02266-3","volume":"8","author":"H Eldar-Finkelman","year":"2002","unstructured":"Eldar-Finkelman H (2002) Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol Med 8(3):126\u201332","journal-title":"Trends Mol Med"},{"issue":"4","key":"3500_CR46","first-page":"32","volume":"31","author":"H Eldar-Finkelman","year":"2011","unstructured":"Eldar-Finkelman H, Martinez A (2011) GSK-3 inhibitors: preclinical and clinical focus on CNS. Front Mol Neurosci 31(4):32","journal-title":"Front Mol Neurosci"},{"issue":"3","key":"3500_CR47","first-page":"271","volume":"9","author":"M Emamghoreishi","year":"2019","unstructured":"Emamghoreishi M, Farrokhi MR, Amiri A, Keshavarz M (2019) The neuroprotective mechanism of cinnamaldehyde against amyloid-\u03b2 in neuronal SHSY5Y cell line: the role of N-methyl-D-aspartate, ryanodine, and adenosine receptors and glycogen synthase kinase-3\u03b2. Avicenna J Phytomed 9(3):271","journal-title":"Avicenna J Phytomed"},{"issue":"4","key":"3500_CR48","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1124\/mol.104.007062","volume":"67","author":"M Enguita","year":"2005","unstructured":"Enguita M, DeGregorio-Rocasolano N, Abad A, Trullas R (2005) Glycogen synthase kinase 3 activity mediates neuronal pentraxin 1 expression and cell death induced by potassium deprivation in cerebellar granule cells. Mol Pharmacol 67(4):1237\u201346","journal-title":"Mol Pharmacol"},{"issue":"15","key":"3500_CR49","doi-asserted-by":"publisher","first-page":"5976","DOI":"10.1021\/ja1112996","volume":"133","author":"L Feng","year":"2011","unstructured":"Feng L, Geisselbrecht Y, Blanck S, Wilbuer A, Atilla-Gokcumen GE, Filippakopoulos P, Kr\u00e4ling K, Celik MA, Harms K, Maksimoska J, Marmorstein R (2011) Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors. J Am Chem Soc 133(15):5976\u201386","journal-title":"J Am Chem Soc"},{"key":"3500_CR50","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00401-002-0587-8","volume":"104","author":"I Ferrer","year":"2002","unstructured":"Ferrer I, Barrachina M, Puig B (2002) Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer\u2019s disease, Pick\u2019s disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol 104:583\u201391","journal-title":"Acta Neuropathol"},{"issue":"1","key":"3500_CR51","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1567205052772713","volume":"2","author":"I Ferrer","year":"2005","unstructured":"Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, Avila JJ (2005) Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer\u2019s disease and tauopathies. Curr Alzheimer Res 2(1):3\u201318","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"3500_CR52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/35094067","volume":"1","author":"R Fodde","year":"2001","unstructured":"Fodde R, Smits R, Clevers H (2001) APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer 1(1):55\u201367","journal-title":"Nat Rev Cancer"},{"key":"3500_CR53","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s007020070034","volume":"107","author":"OV Forlenza","year":"2000","unstructured":"Forlenza OV, Spink JM, Dayanandan R, Anderton BH, Olesen OF, Lovestone S (2000) Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3\u03b2 inhibition and in neurons. J Neur Trans 107:1201\u201312","journal-title":"J Neur Trans"},{"issue":"5","key":"3500_CR54","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1192\/bjp.2019.76","volume":"215","author":"OV Forlenza","year":"2019","unstructured":"Forlenza OV, Radanovic M, Talib LL, Gattaz WF (2019Nov) Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial. Br J Psychiatry 215(5):668\u201374","journal-title":"Br J Psychiatry"},{"issue":"1","key":"3500_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj3590001","volume":"359","author":"S Frame","year":"2001","unstructured":"Frame S, Cohen P (2001) GSK3 takes centre stage more than 20 years after its discovery. Biochem J 359(1):1\u20136","journal-title":"Biochem J"},{"issue":"14","key":"3500_CR56","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1096\/fj.02-0327fje","volume":"16","author":"JL Garrido","year":"2002","unstructured":"Garrido JL, Godoy J, Alvarez A, Bronfman M, Inestrosa NC (2002) Protein kinase C inhibits amyloid \u03b2-peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J 16(14):1982\u20134","journal-title":"FASEB J"},{"issue":"8","key":"3500_CR57","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/j.febslet.2007.03.018","volume":"581","author":"JJ Garrido","year":"2007","unstructured":"Garrido JJ, Sim\u00f3n D, Varea O, Wandosell F (2007) GSK3 alpha and GSK3 beta are necessary for axon formation. FEBS Lett 581(8):1579\u201386","journal-title":"FEBS Letters"},{"issue":"3","key":"3500_CR58","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/jnc.12203","volume":"125","author":"B Georgievska","year":"2013","unstructured":"Georgievska B, Sandin J, Doherty J, M\u00f6rtberg A, Neelissen J, Andersson A, Gruber S, Nilsson Y, Sch\u00f6tt P, Arvidsson PI, Hellberg S (2013) AZD 1080, a novel GSK 3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. J Neurochem 125(3):446\u201356","journal-title":"J Neurochem"},{"issue":"27","key":"3500_CR59","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.2174\/0929867329666220216113517","volume":"29","author":"T Gianferrara","year":"2022","unstructured":"Gianferrara T, Cescon E, Grieco I, Spalluto G, Federico S (2022) Glycogen synthase kinase 3\u03b2 involvement in neuroinflammation and neurodegenerative diseases. Curr Med Chem 29(27):4631\u201397","journal-title":"Curr Med Chem"},{"issue":"5","key":"3500_CR60","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1002\/iub.187","volume":"61","author":"KP Giese","year":"2009","unstructured":"Giese KP (2009) GSK-3: a key player in neurodegeneration and memory. IUBMB Life 61(5):516\u201321","journal-title":"IUBMB Life"},{"issue":"51","key":"3500_CR61","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.1038\/sj.onc.1209954","volume":"25","author":"TD Gilmore","year":"2006","unstructured":"Gilmore TD (2006) Introduction to NF-\u03baB: players, pathways, perspectives. Oncogene 25(51):6680\u20134","journal-title":"Oncogene"},{"issue":"7","key":"3500_CR62","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/sj.npp.1300731","volume":"30","author":"TD Gould","year":"2005","unstructured":"Gould TD, Manji HK (2005) Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 30(7):1223\u201337","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"3500_CR63","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.neuint.2012.07.003","volume":"61","author":"HF Green","year":"2012","unstructured":"Green HF, Nolan YM (2012) GSK-3 mediates the release of IL-1\u03b2, TNF-\u03b1 and IL-10 from cortical glia. Neurochem Int 61(5):666\u201371","journal-title":"Neurochem Int"},{"issue":"1","key":"3500_CR64","doi-asserted-by":"publisher","first-page":"18045","DOI":"10.1038\/s41598-019-54557-5","volume":"9","author":"G Griebel","year":"2019","unstructured":"Griebel G, Stemmelin J, Lopez-Grancha M, Boulay D, Boquet G, Slowinski F, Pichat P, Beesk\u00e9 S, Tanaka S, Mori A, Fujimura M (2019) The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer\u2019s disease in rodents. Sci Rep 9(1):18045","journal-title":"Sci Rep"},{"issue":"9","key":"3500_CR65","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1021\/np060092r","volume":"70","author":"M Hamann","year":"2007","unstructured":"Hamann M, Alonso D, Mart\u00edn-Aparicio E, Fuertes A, P\u00e9rez-Puerto MJ, Castro A, Morales S, Navarro ML, del Monte-Mill\u00e1n M, Medina M, Pennaka H (2007) Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure\u2013activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer\u2019s Disease. J Nat Prod 70(9):1397\u2013405","journal-title":"J Nat Prod"},{"issue":"11","key":"3500_CR66","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/nn1997","volume":"10","author":"UK Hanisch","year":"2007","unstructured":"Hanisch UK, Kettenmann H (2007) Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10(11):1387\u201394","journal-title":"Nat Neurosci"},{"issue":"10","key":"3500_CR67","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S0960-9822(98)70226-X","volume":"8","author":"MJ Hart","year":"1998","unstructured":"Hart MJ, De Los Santos R, Albert IN, Rubinfeld B, Polakis P (1998) Downregulation of \u03b2-catenin by human Axin and its association with the APC tumor suppressor, \u03b2-catenin and GSK3\u03b2. Curr Biol 8(10):573\u201381","journal-title":"Curr Biol"},{"issue":"1","key":"3500_CR68","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1471-4159.2005.03363.x","volume":"95","author":"C Hawkes","year":"2005","unstructured":"Hawkes C, Jhamandas JH, Kar S (2005) Selective loss of basal forebrain cholinergic neurons by 192 IgG-saporin is associated with decreased phosphorylation of Ser9 glycogen synthase kinase-3\u03b2. J Neurochem 95(1):263\u201372","journal-title":"J Neurochem"},{"issue":"18","key":"3500_CR69","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1101\/gad.1228704","volume":"18","author":"MS Hayden","year":"2004","unstructured":"Hayden MS, Ghosh S (2004) Signaling to NF-\u03baB. Genes Dev 18(18):2195\u2013224","journal-title":"Genes Dev"},{"issue":"1\u20132","key":"3500_CR70","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jneuroim.2006.11.017","volume":"184","author":"MT Heneka","year":"2007","unstructured":"Heneka MT, O\u2019Banion MK (2007) Inflammatory processes in Alzheimer\u2019s disease. J Neuroimmunol 184(1\u20132):69\u201391","journal-title":"J Neuroimmunol"},{"issue":"28","key":"3500_CR71","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1016\/j.febslet.2008.10.026","volume":"582","author":"F Hern\u00e1ndez","year":"2008","unstructured":"Hern\u00e1ndez F, Avila J (2008) The role of glycogen synthase kinase 3 in the early stages of Alzheimer\u2019s disease. FEBS Letters. 582(28):3848\u201354","journal-title":"FEBS Letters."},{"issue":"8","key":"3500_CR72","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.neurobiolaging.2003.04.002","volume":"24","author":"F Hern\u00e1ndez","year":"2003","unstructured":"Hern\u00e1ndez F, Lucas JJ, Cuadros R, Avila J (2003) GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms. Neurobiol Aging 24(8):1087\u201394","journal-title":"Neurobiol Aging"},{"issue":"2","key":"3500_CR73","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.expneurol.2009.09.011","volume":"223","author":"F Hern\u00e1ndez","year":"2010","unstructured":"Hern\u00e1ndez F, de Barreda EG, Fuster-Matanzo A, Lucas JJ, Avila J (2010) GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol 223(2):322\u20135","journal-title":"Exp Neurol"},{"issue":"1","key":"3500_CR74","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1749-6632.2000.tb06937.x","volume":"920","author":"C Hock","year":"2000","unstructured":"Hock C, Maddalena A, Heuser I, Naber D, Oertel W, Von Der Kammer H, Wienrich M, Raschig A, Deng M, Growdon JH, Nitsch RM (2000) Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid \u03b2-peptide in patients with Alzheimer\u2019s disease. Annals New York Acad Sci 920(1):285\u201391","journal-title":"Annals New York Acad Sci"},{"issue":"4","key":"3500_CR75","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1042\/bst0280441","volume":"28","author":"NM Hooper","year":"2000","unstructured":"Hooper NM, Turner AJ (2000) Protein processing mechanisms: from angiotensin-converting enzyme to Alzheimer\u2019s disease. Biochem Soc Trans 28(4):441\u20136","journal-title":"Biochem Soc Trans"},{"issue":"11","key":"3500_CR76","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2174\/0929867023370121","volume":"9","author":"NM Hooper","year":"2002","unstructured":"Hooper NM, Turner AJ (2002) The search for \u03b1-secretase and its potential as a therapeutic approach to Alzheimer\u2019s disease. Curr Med Chem 9(11):1107\u201319","journal-title":"Curr Med Chem"},{"key":"3500_CR77","first-page":"379","volume":"2","author":"NM Hooper","year":"2002","unstructured":"Hooper NM, Trew AJ, Parkin ET, Turner AJ (2002) The role of proteolysis in Alzheimer\u2019s disease. Cell Peptid Immune Funct Dis 2:379\u201390","journal-title":"Cell Peptid Immune Funct Dis"},{"issue":"6","key":"3500_CR78","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/j.1471-4159.2007.05194.x","volume":"104","author":"C Hooper","year":"2008","unstructured":"Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer\u2019s disease. J Neurochem 104(6):1433\u20139","journal-title":"J Neurochem"},{"issue":"7","key":"3500_CR79","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1073\/pnas.93.7.2719","volume":"93","author":"M Hoshi","year":"1996","unstructured":"Hoshi M, Takashima A, Noguchi K, Murayama M, Sato M, Kondo S, Saitoh Y, Ishiguro K, Hoshino T, Imahori K (1996) Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I\/glycogen synthase kinase 3beta in brain. Proc Nat Acad Sci 93(7):2719\u201323","journal-title":"Proc Nat Acad Sci"},{"issue":"26","key":"3500_CR80","doi-asserted-by":"publisher","first-page":"8819","DOI":"10.1523\/JNEUROSCI.1334-10.2010","volume":"30","author":"X Hu","year":"2010","unstructured":"Hu X, Zhou X, He W, Yang J, Xiong W, Wong P, Wilson CG, Yan R (2010) BACE1 deficiency causes altered neuronal activity and neurodegeneration. J Neurosci 30(26):8819\u201329","journal-title":"J Neurosci"},{"issue":"4","key":"3500_CR81","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3233\/JAD-2012-120688","volume":"32","author":"HC Huang","year":"2012","unstructured":"Huang HC, Xu K, Jiang ZF (2012) Curcumin-mediated neuroprotection against amyloid-\u03b2-induced mitochondrial dysfunction involves the inhibition of GSK-3\u03b2. J Alzheimer\u2019s Dis 32(4):981\u201396","journal-title":"J Alzheimer's Dis"},{"issue":"4","key":"3500_CR82","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.nic.2005.09.009","volume":"15","author":"BP Imbimbo","year":"2005","unstructured":"Imbimbo BP, Lombard J, Pomara N (2005) Pathophysiology of Alzheimer\u2019s disease. Neuroimaging Clin 15(4):727\u201353","journal-title":"Neuroimaging Clin"},{"issue":"4\u20135","key":"3500_CR83","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1080\/15216540701242490","volume":"59","author":"NC Inestrosa","year":"2007","unstructured":"Inestrosa NC, Varela-Nallar L, Grabowski CP, Colombres M (2007) Synaptotoxicity in Alzheimer\u2019s disease: the Wnt signaling pathway as a molecular target. IUBMB Life 59(4\u20135):316\u201321","journal-title":"IUBMB Life"},{"issue":"3","key":"3500_CR84","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1021\/acsmedchemlett.7b00463","volume":"9","author":"XY Jiang","year":"2018","unstructured":"Jiang XY, Chen TK, Zhou JT, He SY, Yang HY, Chen Y, Qu W, Feng F, Sun HP (2018) Dual GSK-3\u03b2\/AChE inhibitors as a new strategy for multitargeting anti-Alzheimer\u2019s disease drug discovery. ACS Med Chem Lett 9(3):171\u20136","journal-title":"ACS Med Chem Lett"},{"issue":"207","key":"3500_CR85","doi-asserted-by":"publisher","first-page":"112751","DOI":"10.1016\/j.ejmech.2020.112751","volume":"1","author":"X Jiang","year":"2020","unstructured":"Jiang X, Zhou J, Wang Y, Chen L, Duan Y, Huang J, Liu C, Chen Y, Liu W, Sun H, Feng F (2020) Rational design and biological evaluation of a new class of thiazolopyridyltetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer\u2019s disease. Eur J Med Chem 1(207):112751","journal-title":"Eur J Med Chem"},{"issue":"3","key":"3500_CR86","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1002\/ctm2.50","volume":"10","author":"X Jiang","year":"2020","unstructured":"Jiang X, Lu H, Li J, Liu W, Wu Q, Xu Z, Qiao Q, Zhang H, Gao H, Zhao Q (2020) A natural BACE1 and GSK3\u03b2 dual inhibitor Notopterol effectively ameliorates the cognitive deficits in APP\/PS1 Alzheimer\u2019s mice by attenuating amyloid-\u03b2 and tau pathology. Clin Trans Med 10(3):e50","journal-title":"Clin Trans Med"},{"issue":"1","key":"3500_CR87","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0014-5793(03)00438-1","volume":"546","author":"AM Johnston","year":"2003","unstructured":"Johnston AM, Pirola L, Van Obberghen E (2003) Molecular mechanisms of insulin receptor substrate protein-mediated modulation of insulin signalling. FEBS Lett 546(1):32\u20136","journal-title":"FEBS Letters."},{"key":"3500_CR88","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s11064-006-9128-5","volume":"32","author":"RS Jope","year":"2007","unstructured":"Jope RS, Yuskaitis CJ, Beurel E (2007) Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 32:577\u201395","journal-title":"Neurochem Res"},{"key":"3500_CR89","first-page":"101500","volume":"16","author":"NJ Joshi","year":"2024","unstructured":"Joshi NJ, Reddy AR (2024) Navigating the GSK-3\u03b2 inhibitors as versatile multi-target drug ligands in Alzheimer\u2019s disease intervention\u2013a comprehensive review. Res Chem 16:101500","journal-title":"Res Chem"},{"issue":"10","key":"3500_CR90","doi-asserted-by":"publisher","first-page":"5987","DOI":"10.1007\/s12035-023-03441-5","volume":"60","author":"D Karati","year":"2023","unstructured":"Karati D, Mukherjee S, Roy S (2023) Molecular and structural insight into adenosine A2A receptor in neurodegenerative disorders: a significant target for efficient treatment approach. Mol Neurobiol 60(10):5987\u20136000","journal-title":"Mol Neurobiol"},{"issue":"1","key":"3500_CR91","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1146\/annurev.immunol.18.1.621","volume":"18","author":"M Karin","year":"2000","unstructured":"Karin M, Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-\u03baB activity. Annual Rev Immunol 18(1):621\u201363","journal-title":"Annual Rev Immunol"},{"issue":"125","key":"3500_CR92","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ejmech.2016.09.058","volume":"5","author":"I Khan","year":"2017","unstructured":"Khan I, Tantray MA, Alam MS, Hamid H (2017) Natural and synthetic bioactive inhibitors of glycogen synthase kinase. Eur J Med Chem 5(125):464\u201377","journal-title":"Eur J Med Chem"},{"issue":"6","key":"3500_CR93","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.neuron.2006.10.031","volume":"52","author":"WY Kim","year":"2006","unstructured":"Kim WY, Zhou FQ, Zhou J, Yokota Y, Wang YM, Yoshimura T, Kaibuchi K, Woodgett JR, Anton ES, Snider WD (2006) Essential roles for GSK-3s and GSK-3-primed substrates in neurotrophin-induced and hippocampal axon growth. Neuron 52(6):981\u201396","journal-title":"Neuron."},{"key":"3500_CR94","doi-asserted-by":"crossref","unstructured":"Kirouac L, Rajic AJ, Cribbs DH, Padmanabhan J (2017) Activation of Ras-ERK signaling and GSK-3 by amyloid precursor protein and amyloid beta facilitates neurodegeneration in Alzheimer\u2019s disease. Eneuro4(2):ENEURO.0149-16.2017","DOI":"10.1523\/ENEURO.0149-16.2017"},{"key":"3500_CR95","doi-asserted-by":"crossref","unstructured":"Kojro E, Fahrenholz F (2005) The non-amyloidogenic pathway structure and function of \u03b1-secretases. Alzheimer\u2019s Disease Cell Mol Aspects Amyloid \u03b2 105-27","DOI":"10.1007\/0-387-23226-5_5"},{"issue":"1\u20132","key":"3500_CR96","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.brainres.2005.03.017","volume":"1045","author":"H Kokubo","year":"2005","unstructured":"Kokubo H, Kayed R, Glabe CG, Saido TC, Iwata N, Helms JB, Yamaguchi H (2005) Oligomeric proteins ultrastructurally localize to cell processes, especially to axon terminals with higher density, but not to lipid rafts in Tg2576 mouse brain. Brain Res 1045(1\u20132):224\u20138","journal-title":"Brain Res"},{"key":"3500_CR97","first-page":"2012","volume":"1","author":"T Kramer","year":"2012","unstructured":"Kramer T, Schmidt B, Lo Monte F (2012) Small-molecule inhibitors of GSK-3: structural insights and their application to Alzheimer\u2019s disease models. Int J Alzheimer\u2019s Dis 1:2012","journal-title":"Int J Alzheimer\u2019s Dis"},{"issue":"10","key":"3500_CR98","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1517\/13543776.15.10.1315","volume":"15","author":"RM Kypta","year":"2005","unstructured":"Kypta RM (2005) GSK-3 inhibitors and their potential in the treatment of Alzheimer\u2019s disease. Exp Opinion Ther Patents 15(10):1315\u201331","journal-title":"Exp Opinion Ther Patents"},{"issue":"21","key":"3500_CR99","doi-asserted-by":"publisher","first-page":"15753","DOI":"10.1074\/jbc.M110.110742","volume":"285","author":"S Lammich","year":"2010","unstructured":"Lammich S, Buell D, Zilow S, Ludwig AK, Nuscher B, Lichtenthaler SF, Prinzen C, Fahrenholz F, Haass C (2010) Expression of the anti-amyloidogenic secretase ADAM10 is suppressed by its 5\u2032-untranslated region. J Biol Chem 285(21):15753\u201360","journal-title":"J Biol Chem"},{"key":"3500_CR100","doi-asserted-by":"crossref","unstructured":"Lauretti E, Dincer O, Pratic\u00f2 D (2020) Glycogen synthase kinase-3 signaling in Alzheimer\u2019s disease. Biochimica et Biophysica Acta (BBA)-Molecular Cell Res 1867(5):118664","DOI":"10.1016\/j.bbamcr.2020.118664"},{"key":"3500_CR101","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1017\/S1462399410001572","volume":"12","author":"B Leber","year":"2010","unstructured":"Leber B, Geng F, Kale J, Andrews DW (2010) Drugs targeting Bcl-2 family members as an emerging strategy in cancer. Expert Rev Mol Med 12:e28","journal-title":"Expert Rev Mol Med"},{"issue":"7","key":"3500_CR102","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1523\/JNEUROSCI.22-07-02478.2002","volume":"22","author":"S Lehnardt","year":"2002","unstructured":"Lehnardt S, Lachance C, Patrizi S, Lefebvre S, Follett PL, Jensen FE, Rosenberg PA, Volpe JJ, Vartanian T (2002) The toll-like receptor TLR4 is necessary for lipopolysaccharide-induced oligodendrocyte injury in the CNS. J Neurosci 22(7):2478\u201386","journal-title":"J Neurosci"},{"key":"3500_CR103","first-page":"2011","volume":"1","author":"P Lei","year":"2011","unstructured":"Lei P, Ayton S, Bush AI, Adlard PA (2011) GSK-3 in neurodegenerative diseases. Int J Alzheimer\u2019s Dis 1:2011","journal-title":"Int J Alzheimer\u2019s Dis"},{"issue":"43","key":"3500_CR104","doi-asserted-by":"publisher","first-page":"33435","DOI":"10.1074\/jbc.M110.149419","volume":"285","author":"A Leroy","year":"2010","unstructured":"Leroy A, Landrieu I, Huvent I, Legrand D, Codeville B, Wieruszeski JM, Lippens G (2010) Spectroscopic studies of GSK3\u03b2 phosphorylation of the neuronal tau protein and its interaction with the N-terminal domain of apolipoprotein E. J Biol Chem 285(43):33435\u201344","journal-title":"J Biol Chem"},{"key":"3500_CR105","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00702-005-0303-7","volume":"113","author":"X Li","year":"2006","unstructured":"Li X, Lu F, Tian Q, Yang Y, Wang Q, Wang JZ (2006) Activation of glycogen synthase kinase-3 induces Alzheimer-like tau hyperphosphorylation in rat hippocampus slices in culture. J Neur Trans 113:93\u2013102","journal-title":"J Neur Trans"},{"key":"3500_CR106","doi-asserted-by":"crossref","unstructured":"Li C, Zhao R, Gao K, Wei Z, Yaoyao Yin M, Ting Lau L, Chui D, Cheung Hoi Yu A (2011) Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer\u2019s disease. Curr Alzheimer Res 8(1):67-80","DOI":"10.2174\/156720511794604543"},{"issue":"1","key":"3500_CR107","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4062\/biomolther.2022.035","volume":"31","author":"CH Lin","year":"2023","unstructured":"Lin CH, Hsieh YS, Sun YC, Huang WH, Chen SL, Weng ZK, Lin TH, Wu YR, Chang KH, Huang HJ, Lee GC (2023) Virtual screening and testing of GSK-3 inhibitors using human SH-SY5Y cells expressing Tau folding reporter and mouse hippocampal primary culture under Tau cytotoxicity. Biomol Ther 31(1):127","journal-title":"Biomol Ther"},{"issue":"2\u20133","key":"3500_CR108","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ijdevneu.2005.11.010","volume":"24","author":"W Liskowsky","year":"2006","unstructured":"Liskowsky W, Schliebs R (2006) Muscarinic acetylcholine receptor inhibition in transgenic Alzheimer-like Tg2576 mice by scopolamine favours the amyloidogenic route of processing of amyloid precursor protein. Int J Dev Neurosci 24(2\u20133):149\u201356","journal-title":"Int J Dev Neurosci"},{"issue":"6","key":"3500_CR109","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1046\/j.1471-4159.2003.02070.x","volume":"87","author":"SJ Liu","year":"2003","unstructured":"Liu SJ, Zhang AH, Li HL, Wang Q, Deng HM, Netzer WJ, Xu H, Wang JZ (2003) Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J Neurochem 87(6):1333\u201344","journal-title":"J Neurochem"},{"issue":"229","key":"3500_CR110","doi-asserted-by":"publisher","first-page":"114095","DOI":"10.1016\/j.ejmech.2021.114095","volume":"5","author":"W Liu","year":"2022","unstructured":"Liu W, Liu X, Liu W, Gao Y, Wu L, Huang Y, Chen H, Li D, Zhou L, Wang N, Xu Z (2022) Discovery of novel \u03b2-carboline derivatives as selective AChE inhibitors with GSK-3\u03b2 inhibitory property for the treatment of Alzheimer\u2019s disease. Eur J Med Chem 5(229):114095","journal-title":"Eur J Med Chem"},{"issue":"1","key":"3500_CR111","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JAD-141959","volume":"45","author":"S Lovestone","year":"2015","unstructured":"Lovestone S, Boada M, Dubois B, H\u00fcll M, Rinne JO, Huppertz HJ, Calero M, Andr\u00e9s MV, G\u00f3mez-Carrillo B, Le\u00f3n T, Del Ser T (2015) A phase II trial of tideglusib in Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 45(1):75\u201388","journal-title":"J Alzheimer's Dis"},{"issue":"1","key":"3500_CR112","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","volume":"17","author":"BT MacDonald","year":"2009","unstructured":"MacDonald BT, Tamai K, He X (2009) Wnt\/\u03b2-catenin signaling: components, mechanisms, and diseases. Dev Cell 17(1):9\u201326","journal-title":"Dev Cell"},{"issue":"2","key":"3500_CR113","doi-asserted-by":"publisher","first-page":"181","DOI":"10.3233\/JAD-2008-15204","volume":"15","author":"A Martinez","year":"2008","unstructured":"Martinez A, Perez DI (2008) GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer\u2019s disease? J Alzheimer\u2019s Dis 15(2):181\u201391","journal-title":"J Alzheimer's Dis"},{"issue":"4","key":"3500_CR114","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/med.10011","volume":"22","author":"A Martinez","year":"2002","unstructured":"Martinez A, Castro A, Dorronsoro I, Alonso M (2002) Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Medic Res Rev 22(4):373\u201384","journal-title":"Medic Res Rev"},{"issue":"6","key":"3500_CR115","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/nrd2111","volume":"6","author":"MP Mazanetz","year":"2007","unstructured":"Mazanetz MP, Fischer PM (2007) Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discover 6(6):464\u201379","journal-title":"Nat Rev Drug Discover"},{"issue":"25","key":"3500_CR116","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.2174\/138161210793176581","volume":"16","author":"M Medina","year":"2010","unstructured":"Medina M, Avila J (2010) Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer\u2019s disease. Curr Pharm Des 16(25):2790\u20138","journal-title":"Curr Pharm Des"},{"issue":"4","key":"3500_CR117","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.bcp.2014.01.013","volume":"88","author":"M Medina","year":"2014","unstructured":"Medina M, Avila J (2014) New perspectives on the role of tau in Alzheimer\u2019s disease. Impl Ther Biochem Pharmacol 88(4):540\u20137","journal-title":"Impl Ther Biochem Pharmacol"},{"issue":"1","key":"3500_CR118","doi-asserted-by":"publisher","first-page":"38553","DOI":"10.1038\/srep38553","volume":"6","author":"S Medunjanin","year":"2016","unstructured":"Medunjanin S, Schleithoff L, Fiegehenn C, Weinert S, Zuschratter W, Braun-Dullaeus RC (2016) GSK-3\u03b2 controls NF-kappaB activity via IKK\u03b3\/NEMO. Sci Rep 6(1):38553","journal-title":"Sci Rep"},{"issue":"1","key":"3500_CR119","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1074-5521(00)00063-6","volume":"7","author":"L Meijer","year":"2000","unstructured":"Meijer L, Thunnissen AM, White AW, Garnier M, Nikolic M, Tsai LH, Walter J, Cleverley KE, Salinas PC, Wu YZ, Biernat J (2000) Inhibition of cyclin-dependent kinases, GSK-3\u03b2 and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol 7(1):51\u201363","journal-title":"Chem Biol"},{"key":"3500_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-4598-10-101","volume":"10","author":"DP Minde","year":"2011","unstructured":"Minde DP, Anvarian Z, R\u00fcdiger SG, Maurice MM (2011) Messing up disorder: how do missense mutations in the tumor suppressor protein APC lead to cancer? Mol Cancer 10:1\u20139","journal-title":"Mol Cancer"},{"issue":"10","key":"3500_CR121","doi-asserted-by":"publisher","first-page":"e77257","DOI":"10.1371\/journal.pone.0077257","volume":"8","author":"DP Minde","year":"2013","unstructured":"Minde DP, Radli M, Forneris F, Maurice MM, R\u00fcdiger SG (2013) Large extent of disorder in Adenomatous Polyposis Coli offers a strategy to guard Wnt signalling against point mutations. PloS One 8(10):e77257","journal-title":"PloS One"},{"issue":"1","key":"3500_CR122","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4103\/0972-2327.40220","volume":"11","author":"S Mishra","year":"2008","unstructured":"Mishra S, Palanivelu K (2008) The effect of curcumin (turmeric) on Alzheimer\u2019s disease: an overview. Annals Indian Acad Neurol 11(1):13\u20139","journal-title":"Annals Indian Acad Neurol"},{"key":"3500_CR123","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/BF00229744","volume":"165","author":"FJ Moreno","year":"1996","unstructured":"Moreno FJ, Mu\u00f1oz-Monta\u00f1o JR, Avila J (1996) Glycogen synthase kinase 3 phosphorylation of different residues in the presence of different factors: analysis on tau protein. Mol Cell Biochem 165:47\u201354","journal-title":"Mol Cell Biochem"},{"issue":"5","key":"3500_CR124","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/sj.mp.4001483","volume":"9","author":"A Mudher","year":"2004","unstructured":"Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, Mears A, Berg S, MacKay D, Asuni AA, Bhat R (2004) GSK-3\u03b2 inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psych 9(5):522\u201330","journal-title":"Mol Psychiatry"},{"issue":"2","key":"3500_CR125","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2353\/ajpath.2008.070693","volume":"172","author":"D Muyllaert","year":"2008","unstructured":"Muyllaert D, Terwel D, Kremer A, Sennvik K, Borghgraef P, Devijver H, Dewachter I, Van Leuven F (2008) Neurodegeneration and neuroinflammation in cdk5\/p25-inducible mice: a model for hippocampal sclerosis and neocortical degeneration. Am J Pathol 172(2):470\u201385","journal-title":"Am J Pathol"},{"issue":"6","key":"3500_CR126","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1002\/jcb.21575","volume":"103","author":"MH Ni","year":"2008","unstructured":"Ni MH, Wu CC, Chan WH, Chien KY, Yu JS (2008) GSK-3 mediates the okadaic acid-induced modification of collapsin response mediator protein-2 in human SK-N-SH neuroblastoma cells. J Cell Biochem 103(6):1833\u201348","journal-title":"J Cell Biochem"},{"issue":"1","key":"3500_CR127","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/00005072-199701000-00007","volume":"56","author":"JJ Pei","year":"1997","unstructured":"Pei JJ, Tanaka T, Tung YC, Braak EV, Iqbal K, Grundke-Iqbal I (1997) Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 56(1):70\u20138","journal-title":"J Neuropathol Exp Neurol"},{"issue":"12","key":"3500_CR128","first-page":"1810","volume":"3","author":"C Peifer","year":"2008","unstructured":"Peifer C, Alessi DR (2008) Small-molecule inhibitors of PDK1. ChemMedChem Chemistry Enabling Drug Discovery. 3(12):1810\u201338","journal-title":"ChemMedChem Chemistry Enabling Drug Discovery."},{"issue":"5","key":"3500_CR129","first-page":"516","volume":"26","author":"A Petit-Paitel","year":"2010","unstructured":"Petit-Paitel A (2010) GSK-3beta: a central kinase for neurodegenerative diseases? Med Sci M\/S. 26(5):516\u201321","journal-title":"Med Sci M\/S."},{"issue":"6938","key":"3500_CR130","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nature01640","volume":"423","author":"CJ Phiel","year":"2003","unstructured":"Phiel CJ, Wilson CA, Lee VM, Klein PS (2003) GSK-3\u03b1 regulates production of Alzheimer\u2019s disease amyloid-\u03b2 peptides. Nature 423(6938):435\u20139","journal-title":"Nature."},{"issue":"11","key":"3500_CR131","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1523\/JNEUROSCI.23-11-04499.2003","volume":"23","author":"G Pigino","year":"2003","unstructured":"Pigino G, Morfini G, Pelsman A, Mattson MP, Brady ST, Busciglio J (2003) Alzheimer\u2019s presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci 23(11):4499\u2013508","journal-title":"J Neurosci"},{"issue":"1\u20132","key":"3500_CR132","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0169-328X(03)00233-X","volume":"116","author":"P Preece","year":"2003","unstructured":"Preece P, Virley DJ, Costandi M, Coombes R, Moss SJ, Mudge AW, Jazin E, Cairns NJ (2003) \u03b2-Secretase (BACE) and GSK-3 mRNA levels in Alzheimer\u2019s disease. Mol Brain Res 116(1\u20132):155\u20138","journal-title":"Mol Brain Res"},{"issue":"01\/02","key":"3500_CR133","first-page":"51","volume":"83","author":"Y Qi","year":"2017","unstructured":"Qi Y, Dou DQ, Jiang H, Zhang BB, Qin WY, Kang K, Zhang N, Jia D (2017) Arctigenin attenuates learning and memory deficits through PI3k\/Akt\/GSK-3\u03b2 pathway reducing tau hyperphosphorylation in A\u03b2-induced AD mice. Planta Medica 83(01\/02):51\u20136","journal-title":"Planta Medica."},{"issue":"12","key":"3500_CR134","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1084\/jem.20081588","volume":"205","author":"H Qing","year":"2008","unstructured":"Qing H, He G, Ly PT, Fox CJ, Staufenbiel M, Cai F, Zhang Z, Wei S, Sun X, Chen CH, Zhou W (2008) Valproic acid inhibits A\u03b2 production, neuritic plaque formation, and behavioral deficits in Alzheimer\u2019s disease mouse models. J Exp Med 205(12):2781\u20139","journal-title":"J Exp Med"},{"issue":"1","key":"3500_CR135","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1046\/j.1471-4159.1997.69010191.x","volume":"69","author":"CH Reynolds","year":"1997","unstructured":"Reynolds CH, Nebreda AR, Gibb GM, Utton MA, Anderton BH (1997) Reactivating kinase\/p38 phosphorylates \u03c4 protein in vitro. J Neurochem 69(1):191\u20138","journal-title":"J Neurochem"},{"issue":"3","key":"3500_CR136","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/j.1582-4934.2008.00344.x","volume":"13","author":"K Rezai-Zadeh","year":"2009","unstructured":"Rezai-Zadeh K, Douglas Shytle R, Bai Y, Tian J, Hou H, Mori T, Zeng J, Obregon D, Town T, Tan J (2009) Flavonoid-mediated presenilin-1 phosphorylation reduces Alzheimer\u2019s disease \u03b2-amyloid production. J Cell Mol Med 13(3):574\u201388","journal-title":"J Cell Mol Med"},{"issue":"1","key":"3500_CR137","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4103\/0028-3886.30420","volume":"55","author":"M Robert","year":"2007","unstructured":"Robert M, Mathuranath PS (2007) Tau and tauopathies. Neurol India 55(1):11","journal-title":"Neurol India."},{"issue":"6699","key":"3500_CR138","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/26261","volume":"395","author":"DM Rothwarf","year":"1998","unstructured":"Rothwarf DM, Zandi E, Natoli G, Karin M (1998) IKK-\u03b3 is an essential regulatory subunit of the I\u03baB kinase complex. Nature 395(6699):297\u2013300","journal-title":"Nature"},{"issue":"5264","key":"3500_CR139","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1126\/science.272.5264.1023","volume":"272","author":"B Rubinfeld","year":"1996","unstructured":"Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P (1996) Binding of GSK3\u03b2 to the APC-\u03b2-catenin complex and regulation of complex assembly. Science 272(5264):1023\u20136","journal-title":"Science"},{"issue":"2","key":"3500_CR140","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1083\/jcb.200505078","volume":"171","author":"KA Ryan","year":"2005","unstructured":"Ryan KA, Pimplikar SW (2005) Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J Cell Biol 171(2):327\u201335","journal-title":"J Cell Biol"},{"issue":"1","key":"3500_CR141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1742-2094-6-41","volume":"6","author":"A Salminen","year":"2009","unstructured":"Salminen A, Kauppinen A, Suuronen T, Kaarniranta K, Ojala J (2009) ER stress in Alzheimer\u2019s disease: a novel neuronal trigger for inflammation and Alzheimer\u2019s pathology. J Neuroinflamm 6(1):1\u20133","journal-title":"J Neuroinflamm"},{"issue":"1","key":"3500_CR142","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.bmc.2010.11.040","volume":"19","author":"A Samadi","year":"2011","unstructured":"Samadi A, Valderas C, De Los R\u00edos C, Bastida A, Chioua M, Gonz\u00e1lez-Lafuente L, Colmena I, Gand\u00eda L, Romero A, Del Barrio L, Mart\u00edn-de-Saavedra MD (2011) Cholinergic and neuroprotective drugs for the treatment of Alzheimer and neuronal vascular diseases. II. Synthesis, biological assessment, and molecular modelling of new tacrine analogues from highly substituted 2-aminopyridine-3-carbonitriles. Bioorgan Med Chem 19(1):122\u201333","journal-title":"Bioorgan Med Chem"},{"issue":"12","key":"3500_CR143","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1016\/j.neurobiolaging.2010.01.006","volume":"32","author":"SF Santos","year":"2011","unstructured":"Santos SF, Tasiaux B, Sindic C, Octave JN (2011) Inhibition of neuronal calcium oscillations by cell surface APP phosphorylated on T668. Neurobiol Aging 32(12):2308\u201313","journal-title":"Neurobiol Aging"},{"issue":"4","key":"3500_CR144","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3390\/cells10040721","volume":"10","author":"CL Sayas","year":"2021","unstructured":"Sayas CL, \u00c1vila J (2021) GSK-3 and Tau: a key duet in Alzheimer\u2019s disease. Cells 10(4):721","journal-title":"Cells"},{"key":"3500_CR145","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1023\/A:1006883924775","volume":"167","author":"A Sengupta","year":"1997","unstructured":"Sengupta A, Wu Q, Grundke-Iqbal I, Iqbal K, Singh TJ (1997) Potentiation of GSK-3-catalyzed Alzheimer-like phosphorylation of human tau by cdk5. Molec Cell Biochem 167:99\u2013105","journal-title":"Molec Cell Biochem"},{"issue":"2","key":"3500_CR146","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1586\/14789450.5.2.207","volume":"5","author":"N Sergeant","year":"2008","unstructured":"Sergeant N, Bretteville A, Hamdane M, Caillet-Boudin ML, Grognet P, Bombois S, Blum D, Delacourte A, Pasquier F, Vanmechelen E, Schraen-Maschke S (2008) Biochemistry of Tau in Alzheimer\u2019s disease and related neurological disorders. Exp Rev Proteom 5(2):207\u201324","journal-title":"Exp Rev Proteom"},{"issue":"135","key":"3500_CR147","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.biochi.2017.02.001","volume":"1","author":"R Shakeri","year":"2017","unstructured":"Shakeri R, Kheirollahi A, Davoodi J (2017) Apaf-1: regulation and function in cell death. Biochimie 1(135):111\u201325","journal-title":"Biochimie"},{"issue":"22","key":"3500_CR148","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1016\/j.cub.2004.11.009","volume":"14","author":"SH Shi","year":"2004","unstructured":"Shi SH, Cheng T, Jan LY, Jan YN (2004) APC and GSK-3\u03b2 are involved in mPar3 targeting to the nascent axon and establishment of neuronal polarity. Curr Biol 14(22):2025\u201332","journal-title":"Curr Biol"},{"key":"3500_CR149","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s11064-011-0612-1","volume":"37","author":"C Shi","year":"2012","unstructured":"Shi C, Zheng DD, Wu FM, Liu J, Xu J (2012) The phosphatidyl inositol 3 kinase-glycogen synthase kinase 3\u03b2 pathway mediates bilobalide-induced reduction in amyloid \u03b2-peptide. Neurochem Res 37:298\u2013306","journal-title":"Neurochem Res"},{"issue":"167","key":"3500_CR150","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejmech.2019.02.001","volume":"1","author":"XL Shi","year":"2019","unstructured":"Shi XL, Wu JD, Liu P, Liu ZP (2019) Synthesis and evaluation of novel GSK-3\u03b2 inhibitors as multifunctional agents against Alzheimer\u2019s disease. Eur J Med Chem 1(167):211\u201325","journal-title":"Eur J Med Chem"},{"issue":"1","key":"3500_CR151","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/0014-5793(94)01383-C","volume":"358","author":"TJ Singh","year":"1995","unstructured":"Singh TJ, Zaidi T, Grundke-Iqbal I, Iqbal K (1995) Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by non-proline-dependent protein kinases. FEBS Letters 358(1):4\u20138","journal-title":"FEBS Letters"},{"issue":"1","key":"3500_CR152","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1006\/abbi.1996.0140","volume":"328","author":"TJ Singh","year":"1996","unstructured":"Singh TJ, Grundke-Iqbal I, Iqbal K (1996) Differential phosphorylation of human tau isoforms containing three repeats by several protein kinases. Arch Biochem Biophys 328(1):43\u201350","journal-title":"Arch Biochem Biophys"},{"issue":"2\u20133","key":"3500_CR153","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0014-5793(96)00485-1","volume":"387","author":"TJ Singh","year":"1996","unstructured":"Singh TJ, Wang JZ, Novak M, Kontzekova E, Grundke-Iqbal I, Iqbal K (1996) Calcium\/calmodulin-dependent protein kinase II phosphorylates tau at Ser-262 but only partially inhibits its binding to microtubules. FEBS Lett 387(2\u20133):145\u20138","journal-title":"FEBS Letters"},{"issue":"9","key":"3500_CR154","doi-asserted-by":"publisher","first-page":"e1001087","DOI":"10.1371\/journal.pgen.1001087","volume":"6","author":"O Sofola","year":"2010","unstructured":"Sofola O, Kerr F, Rogers I, Killick R, Augustin H, Gandy C, Allen MJ, Hardy J, Lovestone S, Partridge L (2010) Inhibition of GSK-3 ameliorates A\u03b2 pathology in an adult-onset Drosophila model of Alzheimer\u2019s disease. PLoS Gen 6(9):e1001087","journal-title":"PLoS Gen"},{"issue":"1","key":"3500_CR155","first-page":"29","volume":"43","author":"JQ Song","year":"2008","unstructured":"Song JQ, Chen XC, Zhang J, Huang TW, Zeng YQ, Shen J, Chen LM (2008) JNK\/p38 MAPK involves in ginsenoside Rb1 attenuating beta-amyloid peptide (25\u201335)-induced tau protein hyperphosphorylation in embryo rat cortical neurons. Yao Xuexue Bao Acta Pharmaceutica Sinica 43(1):29\u201334","journal-title":"Yao Xuexue Bao Acta Pharmaceutica Sinica"},{"issue":"61","key":"3500_CR156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbi.2016.07.003","volume":"1","author":"EE Spangenberg","year":"2017","unstructured":"Spangenberg EE, Green KN (2017) Inflammation in Alzheimer\u2019s disease: lessons learned from microglia-depletion models. Brain Behav Immun 1(61):1\u20131","journal-title":"Brain Behav Immun"},{"issue":"52","key":"3500_CR157","doi-asserted-by":"publisher","first-page":"41340","DOI":"10.1074\/jbc.M006219200","volume":"275","author":"K Spittaels","year":"2000","unstructured":"Spittaels K, Van den Haute C, Van Dorpe J, Geerts H, Mercken M, Bruynseels K, Lasrado R, Vandezande K, Laenen I, Boon T, Van Lint J (2000) Glycogen synthase kinase-3\u03b2 phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J Biol Chem 275(52):41340\u20139","journal-title":"J Biol Chem"},{"issue":"1","key":"3500_CR158","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1471-4159.2006.03846.x","volume":"98","author":"T Sugano","year":"2006","unstructured":"Sugano T, Yanagita T, Yokoo H, Satoh S, Kobayashi H, Wada A (2006) Enhancement of insulin-induced PI3K\/Akt\/GSK-3\u03b2 and ERK signaling by neuronal nicotinic receptor\/PKC-\u03b1\/ERK pathway: up-regulation of IRS-1\/-2 mRNA and protein in adrenal chromaffin cells. J Neurochem 98(1):20\u201333","journal-title":"J Neurochem"},{"issue":"14","key":"3500_CR159","doi-asserted-by":"publisher","first-page":"11933","DOI":"10.1074\/jbc.M107182200","volume":"277","author":"W Sun","year":"2002","unstructured":"Sun W, Qureshi HY, Cafferty PW, Sobue K, Agarwal-Mawal A, Neufield KD, Paudel HK (2002) Glycogen synthase kinase-3\u03b2 is complexed with tau protein in brain microtubules. J Biol Chem 277(14):11933\u201340","journal-title":"J Biol Chem"},{"issue":"1","key":"3500_CR160","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1172\/JCI11830","volume":"107","author":"PP Tak","year":"2001","unstructured":"Tak PP, Firestein GS (2001) NF-\u03baB: a key role in inflammatory diseases. J Clin Invest 107(1):7\u201311","journal-title":"J Clin Invest"},{"issue":"s3","key":"3500_CR161","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3233\/JAD-2006-9S335","volume":"9","author":"A Takashima","year":"2006","unstructured":"Takashima A (2006) GSK-3 is essential in the pathogenesis of Alzheimer\u2019s disease. J Alzheimer\u2019s Dis 9(s3):309\u201317","journal-title":"J Alzheimer's Dis"},{"issue":"3","key":"3500_CR162","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/jpet.102.041616","volume":"306","author":"AV Terry","year":"2003","unstructured":"Terry AV, Buccafusco JJ (2003Sep 1) The cholinergic hypothesis of age and Alzheimer\u2019s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306(3):821\u20137","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"3500_CR163","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1749-6632.2000.tb06927.x","volume":"920","author":"G Tesco","year":"2000","unstructured":"Tesco G, Tanzi RE (2000) GSK3\u03b2 forms a tetrameric complex with endogenous PS1-CTF\/NTF and \u03b2-catenin: effects of the D257\/D385A and FAD-linked mutations. Annals New York Acad Sci 920(1):227\u201332","journal-title":"Annals New York Acad Sci"},{"issue":"2","key":"3500_CR164","first-page":"226","volume":"9","author":"AK Thakur","year":"2018","unstructured":"Thakur AK, Kamboj P, Goswami K, Ahuja KJ (2018) Pathophysiology and management of Alzheimer\u2019s disease: an overview. J Anal Pharm Res 9(2):226\u201335","journal-title":"J Anal Pharm Res"},{"issue":"1","key":"3500_CR165","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ab.2006.10.003","volume":"360","author":"M Tsukane","year":"2007","unstructured":"Tsukane M, Yoshizaki C, Yamauchi T (2007) Development and specific induction of apoptosis of cultured cell models overexpressing human tau during neural differentiation: implication in Alzheimer\u2019s disease. Anal Biochem 360(1):114\u201322","journal-title":"Anal Biochem"},{"issue":"9","key":"3500_CR166","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1358\/dnp.2003.16.9.829337","volume":"16","author":"J Van Wauwe","year":"2003","unstructured":"Van Wauwe J, Haefner B (2003) Glycogen synthase kinase-3 as drug target: from wallflower to center of attention. Drug News Perspect 16(9):557\u201365","journal-title":"Drug News Perspect"},{"issue":"1","key":"3500_CR167","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0006-8993(98)00103-6","volume":"797","author":"SJ Vannucci","year":"1998","unstructured":"Vannucci SJ, Koehler-Stec EM, Li K, Reynolds TH, Clark R, Simpson IA (1998) GLUT4 glucose transporter expression in rodent brain: effect of diabetes. Brain Res 797(1):1\u20131","journal-title":"Brain Res"},{"key":"3500_CR168","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/978-94-007-2993-3_22","volume":"6","author":"S Vidyadaran","year":"2012","unstructured":"Vidyadaran S, Ramasamy R, Seow HF (2012) Immunomodulatory potential of mesenchymal stem cells on microglia. Stem Cells and Cancer Stem Cells, Therapeutic Applications in Disease and Injury. 6:261\u201372","journal-title":"Stem Cells and Cancer Stem Cells, Therapeutic Applications in Disease and Injury."},{"issue":"4","key":"3500_CR169","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1152\/physiol.00009.2008","volume":"23","author":"T Wakabayashi","year":"2008","unstructured":"Wakabayashi T, De Strooper B (2008) Presenilins: members of the \u03b3-secretase quartets, but part-time soloists too. Physiology 23(4):194\u2013204","journal-title":"Physiol"},{"issue":"1","key":"3500_CR170","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S0014-5793(98)01090-4","volume":"436","author":"JZ Wang","year":"1998","unstructured":"Wang JZ, Wu Q, Smith A, Grundke-Iqbal I, Iqbal K (1998) \u03c4 is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase. FEBS Lett 436(1):28\u201334","journal-title":"FEBS Letters"},{"issue":"1249","key":"3500_CR171","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.brainres.2008.10.046","volume":"16","author":"H Wang","year":"2009","unstructured":"Wang H, Wang R, Zhao Z, Ji Z, Xu S, Holscher C, Sheng S (2009) Coexistences of insulin signaling-related proteins and choline acetyltransferase in neurons. Brain Res 16(1249):237\u201343","journal-title":"Brain Res"},{"issue":"10","key":"3500_CR172","doi-asserted-by":"publisher","first-page":"e13393","DOI":"10.1371\/journal.pone.0013393","volume":"5","author":"Q Wang","year":"2010","unstructured":"Wang Q, Sun SY, Khuri F, Curran WJ, Deng X (2010) Mono-or double-site phosphorylation distinctly regulates the proapoptotic function of Bax. PLoS One 5(10):e13393","journal-title":"PLoS One"},{"key":"3500_CR173","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1007\/s10495-010-0547-z","volume":"15","author":"L Wang","year":"2010","unstructured":"Wang L, Yang HJ, Xia YY, Feng ZW (2010) Insulin-like growth factor 1 protects human neuroblastoma cells SH-EP1 against MPP+-induced apoptosis by AKT\/GSK-3\u03b2\/JNK signaling. Apoptosis 15:1470\u20139","journal-title":"Apoptosis"},{"issue":"36","key":"3500_CR174","doi-asserted-by":"publisher","first-page":"32131","DOI":"10.1021\/acsomega.2c03368","volume":"7","author":"N Wang","year":"2022","unstructured":"Wang N, Liu W, Zhou L, Liu W, Liang X, Liu X, Xu Z, Zhong T, Wu Q, Jiao X, Chen J (2022) Design, synthesis, and biological evaluation of Notopterol derivatives as triple inhibitors of AChE\/BACE1\/GSK3\u03b2 for the treatment of Alzheimer\u2019s disease. ACS Omega 7(36):32131\u201352","journal-title":"ACS Omega"},{"key":"3500_CR175","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/9781119715672.ch11","volume":"13","author":"J Warren","year":"2024","unstructured":"Warren J, Collinge J, Fox N, Mead S, Mummery C, Rohrer J, Rossor M, Schott J, Weil R (2024) Cognitive impairment and dementia. Neurol A Queen Square Textbook. 13:319\u201367","journal-title":"Neurol A Queen Square Textbook."},{"issue":"11","key":"3500_CR176","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/md14110200","volume":"14","author":"J Wiese","year":"2016","unstructured":"Wiese J, Imhoff JF, Gulder TA, Labes A, Schmaljohann R (2016) Marine fungi as producers of benzocoumarins, a new class of inhibitors of glycogen-synthase-kinase 3\u03b2. Marine Drugs 14(11):200","journal-title":"Marine Drugs."},{"issue":"7","key":"3500_CR177","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S0092-8674(00)81466-X","volume":"93","author":"S Yamaoka","year":"1998","unstructured":"Yamaoka S, Courtois G, Bessia C, Whiteside ST, Weil R, Agou F, Kirk HE, Kay RJ, Isra\u00ebl A (1998) Complementation cloning of NEMO, a component of the I\u03baB kinase complex essential for NF-\u03baB activation. Cell 93(7):1231\u201340","journal-title":"Cell"},{"issue":"1","key":"3500_CR178","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1080\/14756366.2022.2086867","volume":"37","author":"N Yan","year":"2022","unstructured":"Yan N, Shi XL, Tang LQ, Wang DF, Li X, Liu C, Liu ZP (2022) Synthesis and biological evaluation of thieno [3, 2-c] pyrazol-3-amine derivatives as potent glycogen synthase kinase 3\u03b2 inhibitors for Alzheimer\u2019s disease. J Enzyme Inhibit Med Chem 37(1):1724\u201336","journal-title":"J Enzyme Inhibit Med Chem"},{"issue":"1","key":"3500_CR179","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/0006-8993(83)91179-4","volume":"280","author":"CM Yates","year":"1983","unstructured":"Yates CM, Simpson J, Gordon A, Maloney AF, Allison Y, Ritchie IM, Urquhart A (1983) Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down\u2019s syndrome. Brain Res 280(1):119\u201326","journal-title":"Brain Res"},{"issue":"1","key":"3500_CR180","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.cell.2004.11.012","volume":"120","author":"T Yoshimura","year":"2005","unstructured":"Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K (2005) GSK-3\u03b2 regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 120(1):137\u201349","journal-title":"Cell"},{"issue":"1","key":"3500_CR181","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrm2308","volume":"9","author":"RJ Youle","year":"2008","unstructured":"Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9(1):47\u201359","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"3500_CR182","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1089\/rej.2014.1657","volume":"18","author":"GF Zeng","year":"2015","unstructured":"Zeng GF, Zong SH, Zhang ZY, Fu SW, Li KK, Fang Y, Lu L, Xiao DQ (2015) The role of 6-gingerol on inhibiting amyloid \u03b2 protein-induced apoptosis in PC12 cells. Rejuv Res 18(5):413\u201321","journal-title":"Rejuv Res"},{"key":"3500_CR183","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12576-020-00757-y","volume":"70","author":"H Zhang","year":"2020","unstructured":"Zhang H, Wang X, Xu P, Ji X, Chi T, Liu P, Zou L (2020) Tolfenamic acid inhibits GSK-3\u03b2 and PP2A mediated tau hyperphosphorylation in Alzheimer\u2019s disease models. J Physiol Sci 70:1\u20131","journal-title":"J Physiol Sci"},{"key":"3500_CR184","doi-asserted-by":"crossref","unstructured":"Zhou F, Gong K, Song B, Ma T, van Laar T, Gong Y, Zhang L. (2012) The APP intracellular domain (AICD) inhibits Wnt signalling and promotes neurite outgrowth. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research. 1823(8):1233-41","DOI":"10.1016\/j.bbamcr.2012.05.011"},{"issue":"1","key":"3500_CR185","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0047-6374(01)00342-6","volume":"123","author":"X Zhu","year":"2001","unstructured":"Zhu X, Castellani RJ, Takeda A, Nunomura A, Atwood CS, Perry G, Smith MA (2001) Differential activation of neuronal ERK, JNK\/SAPK and p38 in Alzheimer disease: the \u2018two hit\u2019 hypothesis. Mechan Ageing Dev 123(1):39\u201346","journal-title":"Mechan Ageing Dev"},{"issue":"5","key":"3500_CR186","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000067426","volume":"11","author":"X Zhu","year":"2002","unstructured":"Zhu X, Lee HG, Raina AK, Perry G, Smith MA (2002) The role of mitogen-activated protein kinase pathways in Alzheimer\u2019s disease. Neurosignals 11(5):270\u201381","journal-title":"Neurosignals"},{"issue":"1","key":"3500_CR187","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3233\/JAD-2010-101434","volume":"23","author":"M Zilkova","year":"2011","unstructured":"Zilkova M, Zilka N, Kovac A, Kovacech B, Skrabana R, Skrabanova M, Novak M (2011) Hyperphosphorylated truncated protein tau induces caspase-3 independent apoptosis-like pathway in the Alzheimer\u2019s disease cellular model. J Alzheimer\u2019s Dis 23(1):161\u20139","journal-title":"J Alzheimer's Dis"},{"issue":"1","key":"3500_CR188","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S0960-9822(01)00002-1","volume":"11","author":"J Zumbrunn","year":"2001","unstructured":"Zumbrunn J, Kinoshita K, Hyman AA, N\u00e4thke IS (2001) Binding of the adenomatous polyposis coli protein to microtubules increases microtubule stability and is regulated by GSK3\u03b2 phosphorylation. Curr Biol 11(1):44\u20139","journal-title":"Curr Biol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03500-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03500-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03500-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T10:51:42Z","timestamp":1742295102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03500-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,21]]},"references-count":188,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3500"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03500-1","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,21]]},"assertion":[{"value":"25 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}